The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adults with health condition(s) that can put them at an increased risk of severe RSV disease It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of participants reporting prompted local reactions within 7 days following investigational product administration
Timeframe: Day 7
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
Timeframe: Day 7
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
Timeframe: 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) throughout the study
Timeframe: 2 months after vaccination
Geometric Mean Titer (GMT) ratio (GMR) , estimated by the ratio of the GMTs for RSV subgroup A (RSV A) and RSV subgroup B (RSV B) neutralizing titers (NTs) with RSVpreF in this study's participants to that in Study C3671013 Japanese older adults
Timeframe: 1 month after vaccination
Pfizer CT.gov Call Center